ACXP....................................https://stockcharts.com/h-sc/ui?s=ACXP&p=W&b=5&g=0&id=p86431144783
Recent ACXP News
- Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update • PR Newswire (US) • 05/12/2026 11:01:00 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/04/2026 08:09:37 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 05/04/2026 08:08:46 PM
- Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026 • PR Newswire (US) • 05/04/2026 12:00:00 PM
- Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase • PR Newswire (US) • 04/29/2026 12:00:00 PM
- Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit • Newsfile • 04/27/2026 12:00:00 PM
- Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update • PR Newswire (US) • 04/20/2026 12:00:00 PM
- Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules • PR Newswire (US) • 04/16/2026 08:01:00 PM
- Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules • PR Newswire (US) • 04/16/2026 12:00:00 PM
- Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors • PR Newswire (US) • 03/30/2026 11:01:00 AM
- Acurx Pharmaceuticals Reports Stronger Cash Position and Clinical Progress in Q4 2025 • IH Market News • 03/13/2026 03:39:02 PM
- Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update • PR Newswire (US) • 03/13/2026 11:01:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 12:59:44 PM
- Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection • PR Newswire (US) • 03/09/2026 12:01:00 PM
- Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update • PR Newswire (US) • 02/16/2026 01:01:00 PM
- USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors • PR Newswire (US) • 02/02/2026 01:00:00 PM
- Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals • PR Newswire (US) • 11/18/2025 01:00:00 PM
- Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update • PR Newswire (US) • 11/12/2025 12:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 12:00:44 PM
- Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens • PR Newswire (US) • 11/10/2025 01:00:00 PM
- Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference • PR Newswire (US) • 10/28/2025 12:00:00 PM
- Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update • PR Newswire (US) • 10/27/2025 12:00:00 PM
- New to The Street to Broadcast Nationwide on Bloomberg TV Tonight at 6:30 PM EST Featuring Roadzen, Spartan Equipment, XION, Metaterra, and YY Group • ACCESS Newswire • 10/25/2025 04:55:00 PM
- New to The Street Show #694 to Broadcast Tonight at 6:30 PM EST as Sponsored Programming on Bloomberg TV Featuring Stardust Power (NASDAQ:SDST), Spartan Equipment, Roadzen (NASDAQ:RDZN), Aeries Technology (NASDAQ:AERT), and XION • ACCESS Newswire • 10/18/2025 05:45:00 PM
- Meet the Companies - New to The Street's Accredited Investor Event Returns October 21-22 at Hudson Yards, NYC • ACCESS Newswire • 10/10/2025 07:35:00 PM
